Anadolu Medical Center
| トルコ | オーストリア | スペイン | |
| 陽子線治療 | から $70,000 | から $80,000 | から $25,550 |
| 腹腔鏡下腎摘出術 | から $12,830 | から $15,000 | から $12,000 |
| 腎摘出術 | から $10,000 | から $22,000 | から $15,000 |
| 腎がん放射線治療 | から $6,500 | から $6,968 | から $4,645 |
| 大腸癌に対する放射線療法 | から $7,000 | から $12,000 | から $10,000 |
ビュレント・カラゴズ教授は、腫瘍生物学と免疫療法を専門とし、アナドル医療センターにて腎臓癌の治療に33年の経験の経験を持つ。
腫瘍学においてトルコ国内第3位にランクされるタンルクル医師は、アナドル医療センターにて腎臓がん治療に精密な専門知識を発揮しています。
Solak医師は、ハジェテペ大学がん研究所での専門的なトレーニングと、Hisar Hospital Intercontinentalでの腎臓がんを含む多様ながん治療における豊富な経験を有しています。
Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.
Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.
Turkey is a high-authority destination for kidney cancer care. Turkish medical centers report success rates up to 95% for kidney surgeries. Facilities utilize Da Vinci XI robotic systems and CyberKnife technology. JCI-accredited hospitals provide specialized teams with rapid access to treatment.
Bookimed Expert Insight: Anadolu Medical Center stands out because it employs over 250 specialized oncologists. This massive scale allows for highly specific sub-specialization in rare renal pathologies. Our data shows hospitals with this volume offer more refined tumor board reviews. This multidisciplinary approach is vital for complex stage 3 or 4 cases.
Patient Consensus: Patients often mention that having a dedicated translator makes the medical process stress-free. Many highlight the relief of moving from arrival to surgery in just a few days.
Turkish oncology centers utilize advanced surgical and systemic therapies for kidney cancer. Primary treatments include da Vinci robotic-assisted nephrectomy and laparoscopic surgery. Patients also access innovative targeted therapy and immunotherapy. High-precision radiation and CyberKnife technologies are standard for complex metastatic cases.
Bookimed Expert Insight: Anadolu Medical Center stands out because it is affiliated with Johns Hopkins Medicine. This brings American oncology protocols to Istanbul at a lower cost. Their multidisciplinary team approach ensures that surgeons and oncologists review every case together. This collaboration often leads to 15% better outcomes in complex cases. Some clinics also offer genomic profiling to tailor drug regimens.
Patient Consensus: Patients often mention the speed of starting treatment after their first arrival. They note that having translators and transfers included helps them focus on recovery.
Turkey reports a 90% to 94% 5-year survival rate for localized kidney cancer. Specialized centers achieve up to 100% technical success using cryotherapy for small tumors. Turkish facilities utilize the Da Vinci robotic system to maintain 95% surgical success rates for partial nephrectomies.
Bookimed Expert Insight: Turkish oncology centers like Anadolu Medical Center or Medipol often perform over 65,000 yearly operations. This massive volume allows surgeons to master robot-assisted partial nephrectomies. High-volume practice helps preserve kidney function while ensuring complete tumor removal.
Patient Consensus: Patients value the speed of diagnosis and the professionalism of Turkish medical teams. Many note that robotic options were available much sooner than in their home countries.